Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977626 | 0.92 | ENPP2 (0.47) | ENPP2TAAR1MMP3IDO1KDM4E | |
| SCHEMBL8992963 | 0.87 | LTA4H (0.46) | ENPP2TAAR1MMP3IDO1KDM4E | |
| SCHEMBL237972 | 0.84 | ENPP2 (0.63) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL8992798 | 0.83 | ENPP2 (0.41) | ENPP2TAAR1MMP3IDO1KDM4E | |
| Benzene SCHEMBL5438521 | 0.81 | ENPP2 (0.61) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL8591999 | 0.80 | MAOB (0.59) | IDO1ACHEMAOB | |
| SCHEMBL6557766 | 0.79 | MEN1 (0.73) | TAAR1IDO1KDM4EACHEMEN1 | |
| SCHEMBL8338095 | 0.79 | MMP3 (0.70) | ENPP2MMP3KDM4ETDP1CTSB | |
| SCHEMBL13525281 | 0.79 | MMP3 (0.56) | MMP3KDM4ETDP1LMNA | |
| SCHEMBL7196848 | 0.78 | ENPP2 (0.53) | ENPP2MMP3KDM4ETDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114394-B1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | claimed |
| EP-2114394-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008100301-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | claimed |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-15 | — | — | US | disclosed |
| CN-116425655-B | Synthesis method of triaryl acrylonitrile | 温州大学新材料与产业技术研究院 | 2025-03-11 | — | — | CN | disclosed |
| CN-115724891-B | Mn-L manganese complex and preparation method and application thereof | 浙江工业大学 | 2025-03-04 | — | — | CN | disclosed |
| CN-116854668-B | Phthalazinone compound, pharmaceutical composition and application thereof | 中国药科大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-119137106-A | Arylbenzisoxazole compounds as IP6K and IPMK inhibitors and methods of use thereof | 北卡罗来纳查佩尔山大学 | 2024-12-13 | — | — | CN | disclosed |
| EP-4472954-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | The University of North Carolina at Chapel Hill (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| CN-118666758-A | Anti-melanoma benzyl pyrimidine compound and preparation method and application thereof | 中国医科大学附属盛京医院 | 2024-09-20 | — | — | CN | disclosed |
| EP-0065447-A1 | Fluor-containing silica catalysts; their preparation, and their use in the preparation of nitriles | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-11-24 | — | — | EP | disclosed |
| US-4356302-A | ANOREXIGENIC AGENTS | G. D. SEARLE & CO. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4260759-A | CONDENSATION OF NITRILES | SCHERING-CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4115395-A | FUNGICIDES, BACTERICIDES | SCHERING CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4107166-A | ANTIFUNGAL, ANTIBACTERIAL | SCHERING CORPORATION (US) | 1978-08-15 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4017500-A | FUNGICIDES, BACTERICIDES | SCHERING CORPORATION (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | ENPP2 285/4885TAAR1 77/4885MMP3 4390/4885 |
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | PCNA, LIG4, TOP2B | ENPP2 4277/4885TAAR1 1109/4885MMP3 4782/4885 |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | PFKL, IP6K2, IP6K1 | ENPP2 1678/4885TAAR1 4719/4885MMP3 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.